Zi-xian N. Wang

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2026

Adjuvant chemo-immunotherapy shows comparable efficacy among mismatch-repair-deficient and mismatch-repair-proficient stage III colon cancer: an exploratory, reconstructed individual patient-level data analysis.

Adjuvant chemo-immunotherapy shows comparable efficacy among mismatch-repair-deficient and mismatch-repair-proficient stage III colon cancer: an exploratory, reconstructed individual patient-level data analysis.

Journal: Journal for immunotherapy of cancer
Published: January 09, 2026

Correction: CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis.

Correction: CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis.

Journal: Oncogene
Published: August 07, 2025

Erratum: Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation: Erratum.

Erratum: Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation: Erratum.

Journal: Theranostics
Published: May 14, 2025

Long-term outcomes of ablation versus surgery in patients with colorectal carcinoma pulmonary oligometastases: a single-center, retrospective cohort study.

Long-term outcomes of ablation versus surgery in patients with colorectal carcinoma pulmonary oligometastases: a single-center, retrospective cohort study.

Journal: International journal of surgery (London, England)
Published: May 09, 2025

Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma.

Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma.

Journal: Gut
Published: April 22, 2025

Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis.

Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis.

Journal: Molecular cancer
Published: December 01, 2024

Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors.

Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors.

Journal: Cancer cell
Published: August 09, 2024

First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.

First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.

Journal: Med (New York, N.Y.)
Published: January 09, 2024

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Journal: Nature medicine
Published: January 08, 2024

Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy.

Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy.

Journal: Science bulletin
Published: August 01, 2023

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.

Journal: Nature medicine
Published: July 30, 2023
Showing 1-12 of 67

Last Updated: 09/26/2026